Biotechnology After Failed Prostate Cancer Study Merck’s Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study – Merck & Co (NYSE:MRK) Read more
Biotechnology First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline – First Wave BioPharma (NASDAQ:FWBI) Read more
Biotechnology FDA Conditionally Approves Expanded Use Of BeiGene’s Combination Drug For Certain Type Of Blood Cancer – BeiGene (NASDAQ:BGNE) Read more
Biotechnology GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study Read more